Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
Status:
Recruiting
Trial end date:
2024-02-22
Target enrollment:
Participant gender:
Summary
Background:
Inflammation can play a role in diseases like heart disease and rheumatoid arthritis. PET
scans can help detect inflammation. Two new drugs may create better PET images.
Objective:
To see if the drugs [11C]ER176 and [11C]MC1 can help image inflammation.
Eligibility:
People ages 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM).
Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed.
Design:
Healthy participants will be screened under protocol 01-M-0254 or 17-M-0181.
Participants with arthritis or IIM will have a screening visit. This will include:
Medical history
Physical exam
Blood and urine tests
Possible CT or X-ray: A machine will take pictures of the body.
Healthy participants will have 1 or 2 visits. They may have urine tests. They may take the
drug celecoxib by mouth. They will have a PET scan. A small amount of one or both study drugs
will be injected through a catheter: A needle will guide a thin plastic tube into an arm
vein. Another catheter will draw blood. They will like on a bed that slides into a machine.
Their vital signs and heart activity will be measured.
Participants with arthritis will have up to 2 visits after screening. They may take celecoxib
and have PET scans.
Participants with IIM will have up to 3 visits after screening. At 1 or 2 visits, they will
take celecoxib and have PET scans. They will have 1 visit where they have an MRI: They will
lie on a table that slides into a machine. The machine takes pictures of the body.